Eli Lilly Plans R&D Investment in China
Eli Lilly plans to invest $100 million in research and development in China over the next five years through Lilly Asian Ventures, a Lilly-owned venture capital firm that makes investments in Asia.
Indianapolis, IN (Nov. 14)-Eli Lilly plans to invest $100 million in research and development (R&D) in China over the next five years through Lilly Asian Ventures, a Lilly-owned venture capital firm that makes investments in Asia.
Lilly Asian Ventures was established in 2007 with a geographic focus on the emerging life-science businesses of east and south Asia, particularly China and India.
Earlier this year, Eli Lilly invested $10 million in BioVeda China (Shanghai), a venture capital fund focused on investment in the life-sciences in China.
In September 2007, Eli Lilly formed an R&D pact with Hutchison MediPharma (Shanghai) for the discovery and development of new clinical candidates in oncology and inflammation. Hutchison MediPharma will receive development milestone payments of $20–29 million per candidate and royalties upon commercialization of a candidate.
Eli Lilly also has a pact with Shanghai ChemExplorer (Shanghai), a contract research organization in China. The companies formed a collaborative R&D pact in 2002.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
